Lilly’s Donanemab Could Be A Near-Term Aduhelm Competitor

Company Will File For Accelerated Approval

 
• By Mandy Jackson
Amyloid plaques forming between neurons
The amyloid plaque surrogate endpoint behind Aduhelm's accelerated approval could benefit donanemab and other drugs • Source: Alamy

More from Neurological

More from Therapeutic Category